IRONWOOD PHARMACEUTICALS INC
For the period ended Jun 30, 2025. Filed Aug 11, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 11, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During the quarter ended June 30, 2025, the following directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K, for the purchase or sale of our securities, the material terms of which are set forth in the table below.
| Name (Title) | Action Taken (Date of Action) | Type of Trading Arrangement | Nature of Trading Arrangement | Duration of Trading Arrangement(1) | Aggregate Number of Securities |
|---|---|---|---|---|---|
| Ronald Silver (Corporate Controller) | Adoption (June 16, 2025) | Rule 10b5-1trading arrangement | Sale | January 15, 2027 | Indeterminable(2) |
| (1) | The dates in this column represent the scheduled expiration date of each director or officer’s Rule 10b5-1 trading arrangement. Each Rule 10b5-1 trading arrangement may terminate earlier than the date provided should all transactions contemplated thereunder occur prior to such date. |
| (2) | Mr. Silver’s Rule 10b5-1 trading arrangement provides for the sale of an indeterminable number of shares of Class A Common Stock that Mr. Silver may purchase under the Company’s employee stock purchase plan. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.